Align Technology, Inc. (NASDAQ:ALGN) Director Joseph Lacob sold 7,669 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $260.00, for a total value of $1,993,940.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Joseph Lacob also recently made the following trade(s):

  • On Wednesday, August 28th, Joseph Lacob sold 10,000 shares of Align Technology stock. The shares were sold at an average price of $177.64, for a total value of $1,776,400.00.

NASDAQ:ALGN opened at $258.97 on Wednesday. The company has a market capitalization of $20.49 billion, a price-to-earnings ratio of 52.64, a price-to-earnings-growth ratio of 2.28 and a beta of 2.07. Align Technology, Inc. has a one year low of $169.84 and a one year high of $334.64. The stock has a 50-day simple moving average of $216.70 and a 200 day simple moving average of $244.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.62 and a current ratio of 1.73.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $1.28 EPS for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.14. The business had revenue of $607.30 million during the quarter, compared to the consensus estimate of $595.29 million. Align Technology had a return on equity of 28.76% and a net margin of 18.28%. The company’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the firm earned $1.24 earnings per share. On average, equities research analysts forecast that Align Technology, Inc. will post 5.17 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Financial Architects Inc bought a new position in Align Technology in the third quarter worth about $119,000. First Allied Advisory Services Inc. lifted its holdings in Align Technology by 4.3% in the third quarter. First Allied Advisory Services Inc. now owns 1,695 shares of the medical equipment provider’s stock worth $312,000 after acquiring an additional 70 shares during the last quarter. Insight Wealth Strategies LLC lifted its holdings in Align Technology by 11.3% in the third quarter. Insight Wealth Strategies LLC now owns 2,672 shares of the medical equipment provider’s stock worth $483,000 after acquiring an additional 271 shares during the last quarter. BBVA USA Bancshares Inc. lifted its holdings in Align Technology by 21.6% in the third quarter. BBVA USA Bancshares Inc. now owns 3,480 shares of the medical equipment provider’s stock worth $629,000 after acquiring an additional 617 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Align Technology by 9.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 67,365 shares of the medical equipment provider’s stock worth $12,188,000 after acquiring an additional 5,584 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

ALGN has been the subject of several recent analyst reports. Bank of America raised their target price on Align Technology from $220.00 to $240.00 and gave the company a “neutral” rating in a research note on Thursday, October 24th. UBS Group set a $230.00 target price on Align Technology and gave the company a “hold” rating in a research note on Friday, July 26th. BidaskClub upgraded Align Technology from a “hold” rating to a “buy” rating in a research note on Monday, October 21st. Barclays lowered their target price on Align Technology from $300.00 to $272.00 and set an “overweight” rating for the company in a research note on Monday, October 7th. Finally, Guggenheim downgraded Align Technology from a “buy” rating to a “neutral” rating and lowered their target price for the company from $250.00 to $200.00 in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $255.27.

About Align Technology

Align Technology, Inc, a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, and restorative and aesthetic dentistry worldwide. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as compliance indicators and compensation for tooth eruption; Invisalign Assist treatment, which offers support to dental practitioners throughout the treatment process, including progress tracking; and Invisalign First Phase I and Invisalign First Comprehensive Phase II package for younger patients with early mixed dentition with a mixture of primary/baby and permanent teeth.

Read More: Do You Need a Fiduciary?

Insider Buying and Selling by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.